The EMA policy on publication of clinical data for medicinal products for human use that came into effect on 1 January 2015 requires the centralized publication of clinical trial results, but it does not resolve the more thorny issue of access to individual patient data (IPD) relative to clinical trial results disclosure.

This article, found on pp. 26-29, discusses transparency trends and the importance of continuing to protect the privacy rights of patients.